Boston Pharmaceuticals Inc. is building on its business of in-licensing assets from larger drug companies that have shifted their focus, now bringing in new programs in cancer and neurological disorders from one of its major partners, GlaxoSmithKline plc.
The Cambridge, MA-based private company said 18 March that it licensed two additional programs from GSK under a deal the two companies started in 2018
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?